Generic Name and Formulations:
Dorzolamide HCl 2%; oph soln; contains benzalkonium chloride.
Merck & Co., Inc.
Indications for TRUSOPT:
Open-angle glaucoma. Ocular hypertension.
Adults and Children:
1 drop 3 times daily.
Hepatic impairment. Severe renal impairment (CrCl <30mL/min): not recommended. Discontinue if ocular effects (eg, conjunctivitis, lid reactions) occur. Soft contact lenses. Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant oral carbonic anhydrase inhibitors: not recommended. May inhibit renal excretion of basic drugs and promote excretion of acidic drugs. May increase salicylate toxicity (acidosis).
Carbonic anhydrase inhibitor (sulfonamide).
Burning, stinging, bitter taste, punctate keratitis, ocular allergic reaction, blurred vision, tearing, dryness, photophobia; possible sulfa-like systemic effects.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy